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The transmembrane protein CD33 is a sialic acid-
binding immunoglobulin-like lectin that regulates
innate immunity but has no known functions in the
brain. We have previously shown that the CD33
gene is a risk factor for Alzheimer’s disease (AD).
Here, we observed increased expression of CD33 in
microglial cells in AD brain. The minor allele of the
CD33 SNP rs3865444, which confers protection
against AD, was associated with reductions in both
CD33 expression and insoluble amyloid beta 42
(Ab42) levels in AD brain. Furthermore, the numbers
of CD33-immunoreactive microglia were positively
correlated with insoluble Ab42 levels and plaque
burden in AD brain. CD33 inhibited uptake and clear-
ance of Ab42 in microglial cell cultures. Finally, brain
levels of insoluble Ab42 as well as amyloid plaque
burden were markedly reduced in APPSwe/PS1DE9/
CD33/ mice. Therefore, CD33 inactivation miti-
gates Ab pathology and CD33 inhibition could repre-
sent a novel therapy for AD.
INTRODUCTION
Alzheimer’s disease (AD) is the most prevalent neurodegenera-
tive disease and the leading cause of dementia among the
elderly. The mechanisms underlying the onset and progression
of neurodegeneration and cognitive decline are incompletely
understood. A major breakthrough in our understanding of AD
was the identification of gene mutations associated with rare
familial AD (FAD) cases. Autosomal dominant mutations in the
amyloid beta (A4) precursor protein (APP) and presenilin 1 and
2 (PSEN1/2) genes greatly accelerate the rate of cognitive
decline leading to early-onset dementia (Bertram et al., 2010;
Tanzi, 2013). The vast majority of AD cases, however, are late-
onset (LOAD) forms, which lack an obvious Mendelian inheri-
tance pattern. LOAD has a strong genetic component and is
probably caused by a combination of multiple risk alleles, each
with modest and partially penetrant effects, and environmental
factors (Bertram et al., 2010). Although apolipoprotein E ε4(APOE ε4) remained for a long time the only confirmed genetic
risk factor for LOAD, it accounts for only 10%–20% of the
LOAD risk, suggesting the existence of additional risk factors
(Liu et al., 2013). Recently, genome-wide association studies
(GWAS) performed on extended cohorts (thousands of individ-
uals) led to the identification of additional confirmed genetic
risk factors for AD: CD33 (Bertram et al., 2008; Hollingworth
et al., 2011; Naj et al., 2011), CLU, BIN1, PICALM, CR1,
CD2AP, EPHA1, ABCA7, MS4A4A/MS4A6E (Harold et al.,
2009; Hollingworth et al., 2011; Lambert et al., 2009; Naj
et al., 2011; Seshadri et al., 2010), and TREM2 (Guerreiro et al.,
2013; Jonsson et al., 2013). Understanding the molecular and
cellular activities of these novel genes, as well as their functional
interactions, should greatly advance our understanding of AD.
The deposition of amyloid beta (Ab)-containing plaques is a
pathological hallmark of both FAD and LOAD. Ab results from
the amyloidogenic processing of APP, which is cleaved by the
sequential action of b-secretase/BACE1 and g-secretase/
Presenilin (Querfurth and LaFerla, 2010). In FAD, both APP and
PSEN1/2mutations lead to enhanced amyloidogenic processing
of APP and enhanced production of the toxic Ab42 species
(Querfurth and LaFerla, 2010). Less is known about the mecha-
nisms of Ab formation, self-assembly, and clearance in LOAD.
Interestingly, several genes linked to LOAD have been shown
to impact Ab generation, aggregation, or clearance (Bertram
et al., 2010), suggesting that Ab dysregulation is a central path-
ogenic mechanism in LOAD. A widely accepted model of AD
pathogenesis is the ‘‘amyloid hypothesis,’’ whereby increased
production and self-assembly of Ab toxic species initiates a
series of progressive changes that ultimately lead to neurode-
generation (Hardy and Selkoe, 2002; Hardy and Higgins, 1992;
Tanzi and Bertram, 2005). In this hypothesis, persistent Ab
proteotoxic stress triggers the hyperphosphorylation and aggre-
gation of the microtubule-associated protein tau, leading to
neurofibrillary tangles, another pathological hallmark of AD
(Tanzi and Bertram, 2005). Therefore, a better understanding of
the mechanisms that regulate the generation and deposition,
as well as clearance, of Ab might improve the therapeutic
approaches in AD.
Two SNPs in the CD33, rs3826656 (Bertram et al., 2008) and
rs3865444 (Hollingworth et al., 2011; Naj et al., 2011), have
been associated with LOAD. The 67 kDa type 1 transmembrane
protein CD33 (Siglec-3) is a member of the sialic acid-binding
immunoglobulin-like lectins (Siglecs) and is expressed inNeuron 78, 631–643, May 22, 2013 ª2013 Elsevier Inc. 631
Figure 1. Increased CD33 Expression in AD
(A) Quantitative real-time PCR analysis of CD33
expression in the frontal cortex reveals increased
CD33 mRNA levels in AD relative to control sub-
jects; CD33 mRNA levels have been normalized
to GAPDH or b-Actin mRNA.
(B) Western blotting detection of CD33 in the
frontal cortex reveals a marked upregulation in AD
cases relative to age-matched controls. A less
pronounced increased expression is also seen for
Iba1. GAPDH served as loading control.
(C) The CD33/GAPDH and CD33/Iba1 protein
ratios are increased in AD patients relative to age-
matched controls.
(D) The levels of CD33 protein are decreased in
carriers of the protective minor (T) allele of the
CD33 SNP rs3865444. Bar graph shows CD33
protein levels in individuals from the indicated
groups (CTRL or AD) and genotypes (G/G versus
G/T or T/T). For (A)–(D), *p < 0.05, **p < 0.01,
***p < 0.001, Student’s t test. Data are represented
as mean ± SEM.
(E) Analysis based on general linear regression
model reveals that the protective minor (T) allele of
rs3865444 is associated with decreased CD33
protein, but not mRNA levels, in both controls and
AD cases (p < 0.05 was considered statistically
significant). See also Figure S1 and Table S1.
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acid residues of glycoproteins and glycolipids, have one or
more immunoreceptor tyrosine-based inhibition motif (ITIM),
and mediate cell-cell interactions that inhibit or restrict immune
responses (Crocker et al., 2012; Pillai et al., 2012). CD33 activity
has been implicated in several processes, such as adhesion pro-
cesses in immune or malignant cells, endocytosis, inhibition of
cytokine release by monocytes, and immune cell growth
(Crocker et al., 2007; von Gunten and Bochner, 2008). To date,
no functions have been described for CD33 in the brain.
Here, we show that CD33 is expressed in microglial cells in the
human brain. CD33 protein levels as well as the number of CD33-
positive microglia are increased in AD brains relative to age-
matched controls. Conversely, we show that the minor allele of
the CD33 SNP rs3865444, which protects against AD, leads to
reductions in both CD33 microglial expression and levels of
insoluble Ab42 in AD brain. Furthermore, the numbers of
CD33-immunoreactive microglia positively correlate with insol-
uble Ab42 levels and the amyloid plaque burden in AD cases.632 Neuron 78, 631–643, May 22, 2013 ª2013 Elsevier Inc.Using cultured primary and BV2 micro-
glial cells, we show that CD33 is both
required and sufficient to inhibit the
microglial uptake of Ab42, thus impairing
Ab42 clearance. Finally, APPSwe/PS1DE9
transgenic mice in which the CD33 gene
was knocked out exhibited a marked
reduction of insoluble Ab42 levels and
Ab plaque burden, indicating that CD33
promotes the Ab42 pathology in vivo.
Collectively, these results suggest thatCD33 activity in microglia promotes Ab42 pathology in AD.
They also raise the possibility that the loss ofmicroglial-degrada-
tive capacity of Ab in AD could be reversed therapeutically by
inhibition of CD33 activity.
RESULTS
Increased CD33 Expression in AD
To assess the role of CD33 in AD pathology, we initially assessed
the expression of CD33 in postmortembrain samples from 25AD
patients and 15 age-matched nondemented controls (cohort
characteristics in Table S1, available online). To investigate the
relationship between CD33 mRNA levels and AD, we performed
quantitative real-time PCR on total mRNA extracted from frozen
cortical samples. This revealed a 5-fold increase in CD33 mRNA
levels in AD cases relative to controls (Figure 1A, p < 0.01,
Student’s t test). Normalization of CD33 mRNA levels using
GAPDH and b-Actin mRNAs led to similar results (Figure 1A).
Next, we asked whether CD33 protein levels are increased in
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CD33 Promotes Amyloid Beta Pathologythe frontal cortex in AD. Western blotting using a CD33-specific
antibody (Hoyer et al., 2008; Rollins-Raval and Roth, 2012)
revealed a 2-fold increase in CD33 protein levels in AD samples
relative to controls (Figures 1B and 1C, p < 0.01, Student’s
t test). This significant increase was also observed when
normalizing CD33 levels to the levels of the microglial marker
Iba1 (Figure 1C, p < 0.05, Student’s t test), indicating that
this difference is not explained by an increased number of micro-
glia in AD. Using stereology-based quantitative methods, we
have previously observed that the total number of Iba1-positive
microglia is not significantly different between AD and nonde-
mented subjects (A.S.-P., T. Gomez-Isla, J.H. Growdon, M.P.
Frosch, and B.T.H., unpublished data). Thus, CD33 mRNA and
protein levels are increased in AD brain.
The rs3865444 SNP in the CD33 gene was previously re-
ported to confer protection against AD (Hollingworth et al.,
2011; Naj et al., 2011). Thus, we investigated whether CD33
expression differed in carriers of the major (G) allele, relative
to the carriers of the minor protective (T) allele. All subjects
were genotyped by the Taqman assay using sequence-specific
primers to differentiate between the alleles (Shen et al., 2009).
We found that the minor protective (T) allele is not associated
with changes in CD33 mRNA levels (Figure 1E; p > 0.05, gen-
eral linear regression model). We used different sets of primers
to amplify different regions of the CD33 mRNA, with similar
results (Figures S1A and S1B). However, remarkably, carriers
of the minor (T) allele had significantly reduced CD33 protein
levels (normalized to GAPDH or Iba1 protein levels), in both
AD and control groups (Figure 1D; p < 0.05, Student’s t test
and Figure S1C). We also found that the protective (T) allele
is associated with decreased CD33 protein levels (normalized
to GAPDH or Iba1 protein levels) in both control and AD groups
(Figure 1E, p < 0.05, general linear regression model). Thus,
although the rs3865444 SNP is located on chromosome 19 at
the 51,727,962 base pair (bp) position, upstream of the 50
UTR of the CD33 gene (51,728,335-51,743,274 bp, forward
strand) (Hollingworth et al., 2011; Naj et al., 2011), it does not
affect CD33 mRNA stability but somehow influences mRNA
translation or protein stability. One possibility is that the
rs3865444 SNP is in linkage disequilibrium with functional var-
iant(s) located in the coding region. The observations of
increased CD33 expression in the AD brain and the decreased
CD33 protein levels in the carriers of the protective allele of the
CD33 SNP rs3865444 strongly suggest a role for CD33 in AD
pathogenesis.
Microglial Localization of CD33 and Relationship to AD
CD33 has previously been shown to be expressed in cells of the
immune and hematopoietic cell systems (Crocker et al., 2007).
Microglial cells are responsible for the immune surveillance of
the brain and regulate critical processes relevant to AD pathol-
ogy, including the uptake and clearance of Ab (Aguzzi et al.,
2013; Prinz et al., 2011). Thus, we next asked whether CD33 is
expressed in microglial cells. Immunolabeling of control and
AD frontal cortex sections, using a CD33-specific antibody
(Hoyer et al., 2008; Rollins-Raval and Roth, 2012) and the micro-
glial marker Iba1 revealed a good colocalization between the two
proteins (Figures 2A and 2C). CD33 was also expressed inneurons (Figures S2D and S2E) but not in astrocytes, oligoden-
drocytes, or endothelial cells (Figures S2G–S2I).
Next, we asked whether the number of CD33-immunoreactive
cells differed between AD and control brains. Sections immuno-
labeled for CD33 and stained with diaminobenzidine (DAB) were
subjected to stereology-based quantifications, using previously
described protocols (Serrano-Pozo et al., 2011). The total
numbers of CD33-positive cells increased by 48.9% in the AD
frontal cortex relative to age-matched controls (Figure S2A, n =
28 AD cases and 18 controls, p < 0.001, Student’s t test). We
then identified the CD33-positive microglia using morphological
criteria (Figures 2B and 2D). Stereology-based quantification of
the numbers of CD33-immunoreactive microglia revealed a
marked increase in the AD frontal cortex relative to age-matched
controls (Figure 2E, n = 28 AD cases and 18 controls, p < 0.001,
Student’s t test). We also asked whether the number of CD33-
positive neurons differed between AD and control subjects. We
found no significant difference between the numbers of CD33-
positive neurons in AD and controls (Figures S2B and S2C).
The levels of CD33 protein normalized to Iba1 protein levels
positively correlated with the numbers of CD33-immunoreactive
microglial cells, as expected (Figure 2F, p = 0.007, Pearson’s
correlation test). To validate these findings, we assessed the
relationship between the levels of CD33 protein and those of
the microglial marker Iba1 using western blotting and frontal
cortex protein extracts. We found a positive correlation between
CD33 and Iba1 levels, both in control (Figure 2G, p = 0.03,
Pearson’s correlation test) and AD (Figure 2H, p = 0.002,
Pearson’s correlation test) cases.
We next asked whether the minor (T) allele of the CD33 SNP
rs3865444 is associated with changes in the number of CD33-
positive microglia. We found that carriers of the protective (T)
allele had lower numbers of CD33-positive microglial cells (Fig-
ures 2I–2K); this effect was dose dependent, i.e., carriers of
two (T) alleles exhibited a dramatic reduction of CD33-positive
microglia numbers relative to carriers of one (T) allele or carriers
of themajor (G) allele (Figure 2L, p < 0.01 T/T versusG/G carriers,
one-way Kruskal-Wallis ANOVA, Dunn’s test). We found that the
minor protective (T) allele is associated with decreased CD33-
immunoreactive microglia numbers in both the control and AD
groups (Figure 2M, p < 0.001 and p < 0.05, respectively, general
linear regression model). Therefore, the numbers of CD33-posi-
tive microglia are increased in AD cases and are reduced in car-
riers of two protective (T) alleles, suggesting that CD33 activity in
microglia might impact the etiology and/or pathogenesis of AD.
CD33 Microglial Expression Correlates with Amyloid
Beta Pathology in AD
Increased production and deposition of aggregation-prone Ab
species are hallmarks of AD pathology (Selkoe, 2012; Tanzi
and Bertram, 2005). We investigated whether Ab levels were
different in carriers of the major (G) allele of the CD33 SNP
rs3865444 in comparison to the carriers of the protective (T)
allele. We generated Tris-buffered saline (TBS)-soluble and for-
mic acid (FA)-soluble fractions from the frontal cortex tissue of
controls and AD cases (Wang et al., 2011), and we used these
fractions for Ab ELISA experiments. Remarkably, we found
that the carriers of the minor (T) allele had significantly reducedNeuron 78, 631–643, May 22, 2013 ª2013 Elsevier Inc. 633
Figure 2. Increased Number of CD33-
Immunoreactive Microglia in AD
(A–A00 and C–C00) Fluorescent immunolabeling re-
veals colocalization between CD33 (red) and the
microglial marker Iba1 (green) in the frontal cortex
of CTRL (A–A00) and AD (C–C00) subjects.
(B and D) CD33 labeling using diaminobenzidine
reveals numerous microglial cells that are positive
for CD33.
(E) Stereology-based quantification reveals
increased numbers of CD33-positive microglial
cells in the frontal cortex of AD cases (n = 28)
relative to controls (n = 18), ***p < 0.001, Student’s
t test.
(F) CD33 protein levels normalized to Iba1 protein
levels positively correlate with the numbers of
CD33-immunoreactive microglia in the AD cases
(n = 25; r = 0.525; p = 0.007, Pearson’s correlation
test).
(G and H) CD33 protein levels correlate with the
levels of the microglial marker Iba1, both in con-
trols (G; n = 15; r = 0.543; p = 0.03, Pearson’s
correlation test) and AD (H; n = 25; r = 0.582;
p = 0.002, Pearson’s correlation test) cases.
(I–K) Carriers of the protective minor (T) allele of
rs386544 exhibit decreased numbers of CD33-
positive microglia. Shown are representative pic-
tures from the frontal cortex of a G/G carrier (I),
G/T carrier (J), and T/T AD carrier (K), stained for
CD33.
(L) Stereology-based quantifications reveal
reduced numbers of CD33-positive microglia in
carriers of two protective (T) alleles of rs3865444
(**p < 0.01 T/T carriers versus G/G carriers, one-
way Kruskal-Wallis ANOVA, Dunn’s test). Data are
represented as mean ± SEM. Scale bars repre-
sent 25 mm.
(M) The protective (T) allele of rs3865444 is
associated with decreased numbers of CD33-
immunoreactive microglia in both controls and AD
cases (general linear regression model, p < 0.05
was considered statistically significant). See also
Figure S2.
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CD33 Promotes Amyloid Beta PathologyFA-soluble Ab42 levels but not FA-soluble Ab40 in comparison to
the carriers of the major (G) allele in AD (Figure 3A, p < 0.01,
Student’s t test). We also observed that the minor protective
(T) allele is associated with decreased levels of both TBS-soluble
Ab40 and FA-soluble Ab42 in AD cases (Figure 3B, p < 0.05
and p < 0.01, respectively, general linear regression model).
Microglial cells regulate Ab levels in the brain by a process of
uptake and degradation, which plays a key role in AD pathogen-
esis (Aguzzi et al., 2013; Prinz et al., 2011). To explore the
relationship between CD33 microglial expression and amyloid
pathology, we labeled the AD frontal cortex with Thioflavin S
(to detect amyloid plaques) and antibodies directed against
CD33 and the microglial marker Iba1. This revealed a broad dis-
tribution of CD33-positive microglia throughout the AD cortex
together with an enrichment of CD33-positive microglia around634 Neuron 78, 631–643, May 22, 2013 ª2013 Elsevier Inc.amyloid plaques (Figure S3). We then explored the possibility
that increased CD33microglial expression in the aging brain pro-
motes Ab pathology by preventing the efficient Ab clearance. We
found that the numbers of CD33-immunoreactive microglia posi-
tively correlated with the levels of FA-soluble Ab42 in AD brain
(Figure 3C, p = 0.02, Spearman’s correlation test). We then
asked whether Ab plaque burden in AD cases correlates with
the numbers of CD33-positive microglia. We estimated the Ab
plaque burden in the frontal cortex of AD subjects as the propor-
tion of area of full-width cortex occupied by Ab-immunoreactive
deposits in sections immunostained with an antibody directed
against Ab (residues 3–7, 10D5) (Serrano-Pozo et al., 2011).
Remarkably, we found a positive correlation between amyloid
plaque burden and numbers of CD33-immunoreactive microglial
cells in AD cases (Figure 3D, p = 0.017, Spearman’s correlation
Figure 3. CD33 Microglial Expression Posi-
tively Correlates with Formic Acid-Soluble
Ab42 Levels and Amyloid Plaque Burden
in AD
(A) Formic acid (FA)-soluble Ab42 levels are
decreased in carriers of the rs3865444 minor (T)
allele. ELISA analysis of Ab40 and Ab42 in FA-
soluble fractions isolated from the frontal cortex of
AD cases of the indicated genotypes (**p < 0.01,
Student’s t test). Data are represented as mean ±
SEM.
(B) The protective rs3865444 (T) allele is associ-
ated with decreased levels of both FA-soluble
Ab42 and TBS-soluble Ab40 in AD cases (n = 25 AD
cases, n = 15 controls, general linear regression
model, p < 0.05 was considered statistically sig-
nificant).
(C) The numbers of CD33-immunoreactive micro-
glia positively correlate with the FA-soluble Ab42
levels in AD cases (n = 25; r = 0.446; p = 0.02,
Spearman’s correlation test).
(D) The numbers of CD33-positive microglia posi-
tively correlate with amyloid plaque burden in AD
brain (n = 25; r = 0.471; p = 0.017; Spearman’s
correlation test). See also Figure S3.
Neuron
CD33 Promotes Amyloid Beta Pathologytest). These results suggest that increased microglial expression
of CD33 prevents Ab clearance and strongly implicate microglial
CD33 function in Ab pathology in AD brain.
CD33 Inactivation Promotes the Uptake of Amyloid Beta
by Microglia
Our genetic, biochemical, and histopathological data strongly
suggest that the activity of CD33 in microglia impacts the accu-
mulation of Ab in the brain. To test for a causal relationship be-
tween CD33 activity and Ab pathology in AD, we employed an
in vitro assay of Ab uptake and clearance, using primary micro-
glia isolated from mice with a constitutive inactivation of the
CD33 gene and littermate wild-type (WT) controls. CD33 inacti-
vation in mice does not lead to obvious developmental, histolog-
ical, and behavioral abnormalities, and CD33/ mice breed
normally (Brinkman-Van der Linden et al., 2003). We established
a mixed glial (microglia/astrocyte) primary culture using the
forebrain of WT and CD33/ postnatal day 1 (P1) pups as
source of cells and subsequently enriched for microglial cells
(Choi et al., 2008; Gorlovoy et al., 2009); the microglial culturesNeuron 78, 631–contained more than 93% microglial
(Iba1-positive) cells. We did not detect
any differences in proliferation, growth,
and morphological parameters between
WT and CD33/ microglia (data not
shown). We stained these cells with a
CD33 antibody that we developed in our
laboratory (Figure S4).
Microglia derived from CD33/ mice
were not immunoreactive to the CD33
antibody, as expected (Figures 4A and
4B). The enriched microglial cultures
were incubated with Ab42 for 3 hr, whichallows efficient Ab42 uptake. Subsequently, the Ab42 was
washed out and the cells were incubated for an additional 3 hr,
to allow for Ab42 degradation (Jiang et al., 2008; Mandrekar
et al., 2009). To visualize the process of Ab42 uptake, we used
fluorescently labeled Ab42 (Lee et al., 2012). Visually, we noted
a strong increase in Ab42 levels in CD33/ microglia relative
to WT microglia (Figures 4A0 and 4B0). Quantification of the fluo-
rescent Ab42 signal revealed a significant increase in Ab42
uptake in CD33/ relative to WT cells (Figure 4C, p < 0.01,
Student’s t test). The process of Ab42 degradation cannot be
assessed by imaging with fluorescently labeled Ab42, because
microglial cells degrade Ab42 but they do not completely
degrade the attached fluorophore (Mandrekar et al., 2009). To
validate the Ab42 uptake findings, and investigate whether
CD33 inactivation impacts Ab42 degradation as well, we
measured Ab42 levels by ELISA on extracts prepared from cul-
tures incubated with unlabeled Ab42 (Figures 4D and 4E). We
found that CD33/ microglia contained increased Ab42 levels
after 3 hr of incubation (Figure 4D), confirming our imaging find-
ings. However, after 3 hr of Ab42washout, we found similar rates643, May 22, 2013 ª2013 Elsevier Inc. 635
Figure 4. CD33 Inactivation Leads to Increased Microglial Uptake of Ab42
(A–A00 0 and B–B00 0) Primary microglial cell cultures were incubated with fluorescently labeled Ab42 for 3 hr and then subjected to immunofluorescent labeling for
CD33 (A and B) and Iba1 (A00 0 and B00 0). Microglial cultures derived from CD33/mice, at postnatal day 1, exhibited a markedly increased Ab42 uptake (compare
A0 and B0). Scale bar represents 25 mM.
(C) Quantification of Ab42 average signal intensity in individual cells reveals a strong increase in Ab42 signal in CD33/ cells relative to WT cells (at least 30 cells
were scored per genotype, **p < 0.01, Student’s t test).
(D and E) Microglial cell cultures were treated with unlabeled Ab42 and incubated for 3 hr. After incubation, cells were either collected for ELISA analysis (t = 0) or
washed and incubated for an additional 3 hr in Ab-free medium, followed by ELISA analysis (t = 3 hr). (D) CD33/microglia exhibit increased Ab42 uptake levels
relative to WT microglia (t = 0) (results were derived from four independent experiments; ***p < 0.001, Student’s t test). (E) Similar rates of Ab42 degradation in
CD33/ and WT microglial cells incubated in the absence of Ab42 for an additional 3 hr (the percentage of remaining Ab42 was the ratio of Ab42 remaining at
t = 3 hr to the total amount of Ab42 internalized at t = 0). Data are represented as mean ± SEM. See also Figure S4.
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CD33 Promotes Amyloid Beta Pathologyof Ab42 degradation in both CD33/ and WT microglia (Fig-
ure 4E). Together, these results suggest that CD33 directly
impacts Ab42 uptake, but not Ab42 degradation, in microglial
cells.
Increased CD33 Levels Inhibit Microglial Uptake of
Amyloid Beta
We next assessed whether increasing CD33 levels impairs Ab42
uptake by microglial cells. For this purpose, we employed the
BV2 microglial cell line, which was previously found to efficiently
take up and degrade exogenously added Ab42 (Jiang et al.,
2008; Mandrekar et al., 2009). Cells transfected with a WT-
CD33 construct displayed a decreased uptake of fluorescently
labeled Ab42 relative to cells transfected with an empty
construct (Figures 5A0, 5B0, and 5E, p < 0.01, one-way ANOVA,636 Neuron 78, 631–643, May 22, 2013 ª2013 Elsevier Inc.Tukey’s test). These results were confirmed by ELISA quantifica-
tions (Figure 5F, p < 0.05, one-way ANOVA, Tukey’s test).
Furthermore, ELISA also revealed that Ab42 was degraded at
similar rates by cells transfected withWT-CD33 or an empty vec-
tor (Figure 5G). Similar differences were observed when a
GFP construct was used as a control (Figures 5E–5G). Thus,
increasing CD33 levels is sufficient to inhibit Ab42 uptake, but
not degradation, by microglial cells.
We next transfected cells with a mutant version of CD33 in
which seven lysine residues from the intracellular C-terminal
domain were mutated to arginine (CD33K7R). This prevents
CD33 ubiquitylation and subsequent internalization from the
plasma membrane (Walter et al., 2008). We confirmed that the
CD33K7R protein displayed enhanced cell surface expression
of CD33 (Figure 5C) in comparison to the CD33WT protein
Figure 5. CD33 Inhibits Microglial Uptake of
Ab42
(A–D00 0) BV2 microglial cells were incubated with
fluorescently labeled Ab42 for 3 hr and then sub-
jected to immunofluorescent labeling for CD33
(A–D) and Iba1 (A00 0–D00 0). Overexpression of WT-
CD33 decreases the amount of internalized Ab42
(compare A0 and B0 ). Expression of an ubiq-
uitylation-defective CD33 variant (K7R-CD33)
further decreases the amount of internalized Ab42
(compare B0 and C0). A CD33 variant lacking the
sialic acid-binding V-type immunoglobulin-like
extracellular domain (DV-Ig-CD33) no longer in-
hibits Ab42 uptake (compare B0, C0, with D0). Scale
bar represents 25 mM.
(E) Quantification of Ab42 signal intensity in indi-
vidual cells transfected with the indicated con-
structs or with an empty vector; at least 30 cells
were scored per condition (*p < 0.05, **p < 0.01,
***p < 0.001, one-way ANOVA, Tukey’s test).
(F and G) BV2 cells were treated with unlabeled
Ab42 and incubated for 3 hr. After incubation, cells
were either collected for ELISA analysis (t = 0) or
washed and incubated for an additional 3 hr in
Ab-free medium, followed by ELISA analysis
(t = 3 hr). (F) WT-CD33 inhibits microglial uptake
of Ab42. ELISA quantifications of Ab42 levels in
BV2 cells transfected with the indicated con-
structs or with empty vector (results were obtained
from four independent experiments; *p < 0.05,
**p < 0.01, one-way ANOVA, Tukey’s test). (G)
CD33 overexpression does not affect the rate of
Ab42 degradation by BV2 cells (the percentage of
remaining Ab42 was the ratio of Ab42 remaining
at t = 3 hr to the total amount of Ab42 internalized
at t = 0). Both empty vector and a GFP vector
served as controls. Data are represented as
mean ± SEM.
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hibition of Ab42 uptake (Figures 5C0 and 5E, p < 0.05 CD33K7R
versus CD33WT, one-way ANOVA, Tukey’s test and Figure 5F)
but did not impair subsequent Ab42 degradation (Figure 5G),
further indicating that CD33 inhibits Ab42 uptake by microglial
cells.
CD33 and the related Siglecs perform their biological func-
tions by interacting with sialic acids, which are attached to the
outer membrane of cells and can mediate cis- or trans-cellularNeuron 78, 631–interactions (Paulson et al., 2012). To
determine whether the interaction be-
tween CD33 and sialic acids is involved
in Ab42 uptake, we employed a CD33
mutant construct in which the sialic
acid-binding V-type Immunoglobulin-like
(V-Ig) domain was deleted (Pe´rez-Oliva
et al., 2011). The mutant CD33DV-Ig pro-
tein is present at the plasma membrane
in BV2 cells and is expressed at levels
similar to CD33WT (Figures 5B and 5D
and Pe´rez-Oliva et al., 2011). Remark-
ably, inhibition of Ab42 uptake by CD33was completely abolished in cells expressing the CD33DV-Ig pro-
tein; Ab42 levels were similar to those in cells expressing empty
vector or GFP (Figures 5E and 5F), indicating that sialic acid
binding is required for CD33 to mediate Ab42 uptake. Collec-
tively, these experiments indicate that CD33 modulates micro-
glial uptake of Ab42. Specifically, lower levels of cell surface
CD33 enhance Ab42 internalization, while higher levels impair
this process. Moreover, interaction of CD33 with sialic acids is
necessary to mediate these effects.643, May 22, 2013 ª2013 Elsevier Inc. 637
Figure 6. CD33 Deletion Decreases Formic
Acid-Soluble Ab42 Levels in APP/PS1 Mice
(A) Western blotting analysis of cortical extracts
reveals increased levels of APP and APP C-ter-
minal fragments (CTFs) in 4-month-old APP/PS1
mice in comparison to controls. However, APP
and APP-CTFs levels are similar in APP/PS1
and APP/PS1/CD33/ mice. b-Actin served as
loading control.
(B) Quantification of APP, a-CTF, and b-CTF levels
in APP/PS1 and APP/PS1/CD33/ mice (n = 9
male mice were analyzed per group).
(C–F) ELISA analysis of Ab40 (C and E) and Ab42
(D and F) in TBS-soluble (C and D) or formic acid
(FA)-soluble (E and F) fractions isolated from the
cortex of 4-month-old male mice of the indicated
genotypes.APP/PS1mice exhibit increased levels
of Ab40 and Ab42 relative to WT and CD33/
mice, as expected. No differences in Ab40 levels
and TBS-soluble Ab42 levels were seen in APP/
PS1 and APP/PS1/CD33/ mice. However, the
FA-soluble Ab42 levels were markedly decreased
in APP/PS1/CD33/ relative to APP/PS1 mice
(n = 9–12mice were analyzed per group, *p < 0.05,
one-way Kruskal-Wallis ANOVA, Dunn’s test).
Data are represented as mean ± SEM. See also
Figure S5.
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The above in vitro experiments, together with our genetic,
biochemical, and histopathological observations, strongly impli-
cate CD33 activity in Ab pathology in AD. To provide direct in vivo
evidence that CD33 activity potentiates Ab pathology in vivo, we
used a model of AD, the APPSwe/PS1DE9 mouse (subsequently
referred to as APP/PS1), in which we inactivated CD33 function.
APP/PS1 mice exhibit elevated Ab (including Ab42) production
and develop amyloid plaques (Jankowsky et al., 2004). APP/
PS1 mice lacking CD33 (APP/PS1/CD33/) were born at
Mendelian ratios and exhibited no gross anatomical defects
(data not shown). We isolated the cortex from 4-month-old638 Neuron 78, 631–643, May 22, 2013 ª2013 Elsevier Inc.APP/PS1 and APP/PS1/CD33/ mice
and their littermate controls and derived
detergent-soluble fractions that we
used for subsequent western blotting as
well as TBS-soluble and FA-soluble
fractions (Wang et al., 2011) that we
used for Ab ELISA experiments. Using
western blotting we found, as expected,
increased and similar levels of full-length
APP and APP C-terminal fragments
(APP-CTF) in both APP/PS1 and APP/
PS1/CD33/ mice as compared to con-
trols (Figures 6A and 6B). BACE1 levels
also did not differ across genotypes
(data not shown).
Next, we asked whether knockout of
CD33 affects Ab levels in the APP/PS1
mice. As expected, we found that Ab40
and Ab42 levels (measured by ELISA) inthe TBS-soluble fraction were markedly increased in APP/PS1
mice relative to WT and CD33/ mice (Figures 6C and 6D).
Furthermore, the levels of Ab40 and Ab42 in the TBS-soluble
fraction were similar in the APP/PS1, APP/PS1/CD33+/, and
APP/PS1/CD33/ mice (Figures 6C and 6D). Remarkably,
however, the levels of Ab42 were significantly decreased in the
FA-soluble fraction of APP/PS1/CD33/ mice relative to
APP/PS1 mice (Figure 6F, p < 0.05 APP/PS1/CD33/ versus
APP/PS1 mice, one-way Kruskal-Wallis ANOVA, Dunn’s test).
This effect was not due to increased numbers of microglial
cells or astrocytes in APP/PS1/CD33/ mice (Figure S5) or
alterations in the levels of either inducible nitric oxide synthase
Figure 7. CD33 Deletion Mitigates Ab Pla-
que Pathology in APP/PS1 Mice
(A–D) Photomicrographs of selected cortical (A
and B) and hippocampal (C and D) fields from 6- to
7-month-old APP/PS1 (A and C) and APP/PS1/
CD33/ (B and D) brains were stained with the
anti-Ab antibody 3D6 to reveal Ab plaques. The Ab
plaque burden is decreased in APP/PS1/CD33/
brains relative to APP/PS1 brains (compare B with
A and D with C).
(E and F) Quantification of amyloid plaque burden
in the cortex (E) and hippocampus (F) of 6- to
7-month-old APP/PS1 and APP/PS1/CD33/
brains (n = 9–11 male mice were analyzed per
group, *p < 0.05, **p < 0.01, Student’s t test). Data
are represented as mean ± SEM. Scale bar rep-
resents 50 mm.
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shown). These data suggest that CD33-deficient microglia
possess increased Ab42 uptake/clearance capacity in vivo and
that the CD33-mediated effect on microglial clearance of Ab42
is cell autonomous.
Finally, we investigated whether CD33 deletion impacts the
process of Ab deposition in the APP/PS1 brain. Ab deposition
is obvious by 6 months in APP/PS1 mice when both compact
and diffuse Ab-containing plaques can be observed in the fore-
brain (Jankowsky et al., 2004). We stained coronal sections
from 6- to 7-month-old control, CD33/, APP/PS1, and APP/
PS1/CD33/ mice with an antibody directed against Ab
(residues 1–5, 3D6) that recognizes both compact and diffuse
Ab plaques (Reilly et al., 2003). The 3D6 antibody did not label
any plaques in control and CD33/ brains (data not shown).Neuron 78, 631–Analysis of the APP/PS1 brains revealed
numerous Ab plaques, both in the cortex
and the hippocampus (Figures 7A and
7C). Sections spanning the cortex or
the hippocampus were subjected to
quantification of amyloid plaque burden.
Remarkably, the Ab plaque burden was
robustly decreased in the APP/PS1/
CD33/ brains relative to the APP/PS1
brains (Figures 7B and 7D). The quantifi-
cation revealed a 37.2% and 33.5%
reduction of Ab plaque burden in the
APP/PS1/CD33/ cortex and hippo-
campus, respectively (Figures 7E and
7F; n = 9–11 animals/group, p < 0.01
and p < 0.05, APP/PS1/CD33/ versus
APP/PS1 cortex and hippocampus,
respectively, Student’s t test). Therefore,
CD33 promotes Ab deposition and
plaque formation in vivo.
DISCUSSION
Despite great strides toward the develop-
ment of an effective therapy, no treatmentis currently able to prevent, delay, or stop AD progression. This
is due in part to our incomplete understanding of AD patho-
genesis. While important advances have been made toward a
better understanding of FAD, comparatively little is known about
LOAD. Great advances in DNA sequencing technologies
coupled with the investigation of large human cohorts have
provided an unprecedented analytic power and have led to the
identification of multiple risk factors for LOAD, thus opening
new research avenues that might advance our understanding
of this devastating disease.
We and others have found that the CD33 gene is associated
with risk for LOAD (Bertram et al., 2008; Hollingworth et al.,
2011; Naj et al., 2011). CD33 is a member of the Siglec family
of lectins that binds sialic acid residues leading to cis (same
CD33-expressing cell) or trans (adjacent cells) interactions that643, May 22, 2013 ª2013 Elsevier Inc. 639
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Paulson et al., 2012). To date, the role of CD33 in the brain has
remained unknown. To bridge this gap, and to understand how
CD33 misregulation contributes to LOAD pathogenesis, we per-
formed a comprehensive analysis of CD33 expression and
mechanism of action, using a combination of human and mouse
genetics, biochemistry, neuropathology, and in vitro modeling.
Based on our findings, we propose that increased CD33 activity
in microglial cells inhibits Ab clearance in LOAD; thus, CD33
inhibition may represent a novel means for preventing and
treating AD.
CD33 Expression Is Increased in AD
We found that the levels of CD33 protein are increased in AD.
This increase was paralleled by an increase in the number of
CD33-immunoreactive microglia. Moreover, the ratio CD33/
Iba1 is also increased in AD, suggesting that individual microglia
display increased CD33 levels in AD. Thus, AD cases are
characterized by both an increase in the number of CD33-immu-
noreactive microglia and an increase in CD33 levels in these
CD33-positive cells. Moreover, the fact that the levels of CD33
mRNA were also strongly increased in AD suggests a potential
upregulation of CD33 transcription in microglial cells; alterna-
tively, the CD33 mRNAmight exhibit increased stability in micro-
glia in the AD brain. It will be important to determine whether
CD33 is part of a broader transcriptional program that operates
in microglial cells in the aging brain and to identify the upstream
activators of such a program.
To further explore the relationship between CD33 expression
and AD, we assessed CD33 expression in carriers of the minor
(T) allele of the CD33 SNP rs3865444, which protects against
AD. We found that the minor (T) allele is associated with reduced
CD33 protein levels, both in the AD and control subjects (Fig-
ure 1E). Interestingly, the levels of CD33mRNAwere not reduced
in the carriers of this allele. The rs3865444 SNP is located
upstream of the 50 UTR of the CD33 gene (Hollingworth et al.,
2011; Naj et al., 2011). One possibility is that the rs3865444
SNP is in linkage disequilibrium with functional variant(s) located
in the coding region. This, in turn, could influence mRNA transla-
tion without affecting mRNA stability. Recently, increased CD33
mRNA levels were independently shown to be associated with
AD; CD33 mRNA levels correlated with Iba1 mRNA levels and
CD33 mRNA expression normalized to Iba1 expression corre-
lated with disease status and Clinical Dementia Rating scores
(Karch et al., 2012). The increased CD33 (mRNA and protein)
levels in the AD brain and decreased CD33 protein levels in the
carriers of the protective allele suggest that increased CD33
expression plays a direct role in the etiology and/or pathogenesis
of AD.
CD33 Is a Modifier of Amyloid Beta Pathology
Several genes associated with LOAD have been shown to be
critically involved in the control of Ab homeostasis. ApoE binds
Ab and influences its oligomerization (Hashimoto et al., 2012).
We recently found that lipidated apoE, in particular its patho-
genic variant apoE4, increases the oligomerization of Ab; as a
consequence, APOE ε4/ε4 AD brains displayed higher levels of
Ab oligomers relative to APOE ε3/ε3 brains (Hashimoto et al.,640 Neuron 78, 631–643, May 22, 2013 ª2013 Elsevier Inc.2012). The LOAD-associated gene Clusterin (CLU) encodes an
extracellular chaperone apolipoprotein J (apoJ) that interacts
with Ab prefibrillar structures and inhibits Ab aggregation
(Yerbury et al., 2007). ApoJ also facilitates the transport of
plasma-derived Ab across the blood-brain barrier (BBB) and
Ab42 clearance at the BBB in mice (Bell et al., 2007). Interest-
ingly, apoJ cooperates with apoE to suppress Ab levels and
deposition in vivo (DeMattos et al., 2004).
Besides the control of Ab self-assembly, LOAD-associated
genes are able to control the trafficking of APP and thus influ-
ence the formation of Ab. A genetic screen in yeast revealed
that several LOAD genes (including PICALM and BIN1) were
modifiers of Ab toxicity and suggested that these genes regulate
the endocytic trafficking of APP (Treusch et al., 2011). Moreover,
PICALMpromotes APP internalization, endocytic trafficking, and
Ab generation in neurons in vitro (Xiao et al., 2012). The ABCA7
LOAD risk gene also regulates APP trafficking, by stimulating
cholesterol efflux, which decreases the levels of APP at the
plasma membrane and Ab generation (Chan et al., 2008). There-
fore, targeting the intracellular trafficking of APP in neuronsmight
represent a novel therapeutic approach in AD.
Our results identify CD33 as a modifier of Ab pathology in vivo.
We observed an association between the protective minor (T)
allele of the CD33 SNP rs3865444 and decreased FA-soluble
Ab42 levels in AD as well as a positive correlation between
CD33 microglial expression and FA-soluble Ab42 levels and
amyloid plaque burden in the AD cortex (Figure 3). Moreover,
CD33 levels directly impact microglial uptake of Ab42 (Figures
4 and 5) and modulate the accumulation of FA-soluble Ab42
and Ab plaque burden in APP/PS1 transgenic mice (Figures 6
and 7). Based on these observations, we propose that increased
activity of CD33 in microglial cells contributes to the etiology
and/or pathogenesis of AD by preventing Ab uptake and thus
potentiating its toxicity.
Taken together, the multiple lines of evidence implicating
multiple LOAD risk genes in the control of Ab production, clear-
ance, and deposition provide additional support for the amyloid
hypothesis of AD by demonstrating that failure of multiple
systems that ensure Ab homeostasis is associated with an
increased risk for developing AD. These findings also suggest
immense therapeutic opportunities, since the identification of
drug targets that are critically involved in control of Ab pathoge-
nicity by the novel LOAD risk genes might provide novel strate-
gies targeting the earliest stages of cognitive decline, well before
the occurrence of overt neurodegeneration.
CD33 Inhibits the Microglial Uptake of Amyloid Beta
Based on our finding that CD33microglial expression is elevated
in AD but decreased in carriers of the protectiveminor (T) allele of
the CD33 SNP rs3865444, we hypothesized that the activity of
CD33 in microglia promotes AD pathogenesis. To test this
hypothesis and to unravel the molecular underpinnings of
CD33 action in microglial cells, we investigated whether CD33
is involved in the process of Ab clearance by microglia. Using
an assay of microglial uptake and clearance optimized for
Ab42 (Jiang et al., 2008), we found that mouse primary microglial
cells lacking CD33 expression exhibit an increased uptake
of Ab42 relative to WT cells (Figures 4A–4D). Interestingly,
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(Figure 4E). In CD33-deficient cells, however, Ab42 clearance
was accelerated, due to the increased overall uptake. To further
explore the involvement of CD33 in Ab42 uptake by microglial
cells, we employed a well-characterized microglial cell line
(BV2) that effectively internalizes and degrades added Ab42
(Mandrekar et al., 2009). We found that microglia overexpressing
WT CD33 were markedly impaired in their capacity to internalize
Ab42 but degraded the internalized Ab42 at a similar rate to
cells transfected with an empty plasmid or a GFP plasmid
(Figures 5E–5G). This finding was also validated by the transfec-
tion with an ubiquitylation-defective CD33 mutant (CD33K7R),
which exhibits enhanced cell surface expression of CD33 (Fig-
ure 5C and Walter et al., 2008) and further exacerbates the inhi-
bition of Ab42 uptake (Figures 5E and 5F). Thus, CD33 directly
modulates uptake, but not degradation, of Ab42 by microglial
cells.
CD33 and the related Siglecs perform their biological func-
tions by interacting with sialic acids, which are attached to the
outer membrane of cells, and can mediate cis- or trans-cellular
interactions (Crocker et al., 2007). To explore the requirement
of sialic acid binding in the process of CD33-mediated microglial
uptake of Ab42, we transfected microglial BV2 cells with a CD33
mutant in which the sialic acid-binding V-type immunoglobulin-
like domain was removed. The mutant CD33DV-Ig protein is pre-
sent at the plasma membrane in BV2 cells and is expressed at
levels similar to CD33WT (Figures 5B and 5D and Pe´rez-Oliva
et al., 2011). Cells expressing the CD33DV-Ig protein were no
longer impaired in their capacity to uptake Ab42, indicating
that sialic acid binding is necessary for the ability of CD33 to
inhibit Ab42 uptake. Collectively, these experiments indicate
that CD33 directlymodulatesmicroglial uptake of Ab42, via inter-
action with sialic acids.
Microglial cells have been suggested to play critical roles
as mediators of Ab clearance in the brain. A previous study
(Grathwohl et al., 2009) challenged this view by showing that
ablation of microglial cells (using drug-induced microglial
toxicity) did not alleviate Ab pathology in two AD mouse models,
within a 4 week time window after the ablation. These results
await confirmation in a setting of prolonged microglial ablation
(several months to years). It also remains to be determined
whether an acute removal of microglial cells has a specific effect
on the dynamics of monomeric and oligomeric as opposed to
fibrillar Ab.
Mounting evidence implicates genes associated with risk for
LOAD in the process of microglial clearance of Ab42. For
example, apoE promotes the clearance of Ab in the brain, partly
through its capacity to enhance Ab uptake and degradation by
microglia (Jiang et al., 2008; Lee et al., 2012). Interestingly,
another LOAD risk gene, ApoJ/Clusterin (CLU) cooperates with
APOE to suppress Ab levels and deposition in PDAPP transgenic
mice (DeMattos et al., 2004). A rare variant of the TREM2 gene
has been recently shown to confer increased risk for LOAD
(Guerreiro et al., 2013; Jonsson et al., 2013). TREM2 is an innate
immune receptor, similar to CD33, and is expressed in a subset
of myeloid cells including microglia (Klesney-Tait et al., 2006).
Remarkably, TREM2 is upregulated in amyloid plaque-associ-
ated microglia in aging APP23 transgenic mice (Frank et al.,2008) and in CRND8 transgenic mice (expressing mutant
KM670/671NL and V717F APP) (Guerreiro et al., 2013) and
promotes the phagocytic clearance of amyloid proteins
(Melchior et al., 2010). Interestingly, TREM2 interacts with
its ligand TREM2-L, expressed by apoptotic neurons, and medi-
ates removal of dying neuronal cells by microglia (Hsieh et al.,
2009).
Our results suggest that CD33 represents a regulator of micro-
glial clearance of Ab and a target for the treatment and preven-
tion of AD. It is interesting to note that therapies targeting
CD33 have already been developed in acute myeloid leukemia
(AML), due to its high membrane expression in myeloid cells
(Jandus et al., 2011; O’Reilly and Paulson, 2009). Naked human-
ized anti-CD33 and calicheamicin-conjugated humanized
murine anti-CD33 antibodies have been developed and tested
in several phase III clinical trials of AML, with mixed results
(Jandus et al., 2011; Jurcic, 2012; Ricart, 2011). This suggests
that the development of a CD33 antibody that is able to
cross the BBB is feasible in principle. A chimeric antibody in
which the CD33 antibody is fused to a monoclonal antibody
against the human insulin receptor could facilitate the recep-
tor-mediated passage of the chimera across the BBB (O’Reilly
and Paulson, 2009). An alternative approach is the development
of small compounds, e.g., sialic acid-based antagonists that
target CD33 specifically and inhibit its function. Furthermore, a
better understanding of CD33 action in microglial cells should
lead to the identification of critical cellular targets that link the
activity of CD33 in microglia to the process of Ab recognition
and uptake and will hopefully lead to the development of novel
therapeutics for the prevention and treatment of AD.
EXPERIMENTAL PROCEDURES
Please see the Supplemental Experimental Procedures for detailed methods
on SNP genotyping, RNA extraction and real-time PCR, immunohistochem-
istry and stereology, assessment of Ab plaque burden in mice, ELISA, western
blot analysis, generation of an anti-mouse CD33 antibody, primary microglia
isolation, cell culture and transfection, Ab uptake, and degradation assays.
Brain Specimens
Formalin-fixed, paraffin-embedded 8-mm-thick sections, as well as frozen
tissue specimens from the fontal cortex of 25 patients with AD and 15 age-
matched nondemented control subjects were obtained from the Massachu-
setts Alzheimer’s Disease Research Center Brain Bank. All the study subjects
or their next of kin gave written informed consent for the brain donation, and
the Massachusetts General Hospital Institutional Review Board approved
the study protocol. The demographic characteristics of both groups are shown
in Table S1. All patients with AD fulfilled the National Institute of Neurological
and Communicative Disorders and Stroke-Alzheimer’s Disease and Related
Disorders Associations criteria for probable AD and the National Institute on
Aging-Reagan Institute criteria for high likelihood of AD.
Animals
APPSwe/PS1DE9 transgenic mice (referred to as APP/PS1) (Jankowsky et al.,
2004) and constitutive CD33 knockout mice (Brinkman-Van der Linden et al.,
2003) were obtained from The Jackson Laboratory (catalog 005864 and
006942, respectively). Both mouse strains are on the C57Bl/6 background.
All mice were housed under standard conditions with free access to food
and water. All animal experiments were performed in accordance with national
guidelines (National Institutes of Health) and approved by Massachusetts
General Hospital and McLaughlin Institute Institutional Animal Care and Use
Committees.Neuron 78, 631–643, May 22, 2013 ª2013 Elsevier Inc. 641
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A general linear regression model adjusting for appropriate covariates was
used to test for allelic association between the rs3865444 SNP and quantita-
tive traits, as implemented in PLINK v1.07 (http://pngu.mgh.harvard.edu/
purcell/plink) (Purcell et al., 2007). To identify covariates that maximize the
regression model’s predictive ability and predict the quantitative traits for
the human samples, we performed a stepwise regression procedure using
age, gender, disease status, postmortem interval, and presence of APOE ε4
allele. The stepwise regression analysis was performed using the R (v2.10.0)
software package (R Development Core Team, 2009). Statistics and correla-
tions of different quantitative traits were performed using the GraphPad Prism
software, version 5.0 (GraphPad). The normality of quantitative trait data sets
was tested with the D’Agostino-Pearson omnibus test. Student’s t test and
Pearson’s correlation test were performed for normally distributed data sets
and Mann-Whitney U and Spearman’s correlation tests otherwise. Multiple
group analyses were performed by one-way ANOVA followed by Tukey’s
post hoc test or by one-way Kruskal-Wallis ANOVA followed by Dunn’s post
hoc test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.neuron.2013.04.014.
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